Key Takeaways
- A quarter of one-offs, not operations: Revenue was nearly flat because GTBL was sold out on old capacity, while consolidated EBITDA and PAT were hit by a ~₹16 crore unrealized forex loss, only 13 days of MBJ consolidation, and a small earthquake restoration charge.
- The capacity unlock is now live: The new fermentation facility started on 26 September, doubling capacity to 990 kiloliters; output begins in Q3 and revenue benefits flow from Q4, which management expects will restore EBITDA margins.
- MBJ is the strategic bet, not yet the earnings driver: The acquisition closed mid-September, and management is still deep-diving its technology base before committing to a 5-year payback or pre-poned revenue trajectory, with alignment targeted by March.
- The Sanofi deal fills the only forward-integration path that does not cannibalize existing customers: The branded, originator portfolio is seen as the sole route into finished dosage forms without hurting the intermediate business that is GTBL's "bread and butter."
- What to watch next quarter: Whether the new fermentation output ramps as guided, whether the unrealised forex loss reverses, and any concrete project confirmations from the MBJ integration deep-dive.
The Quarter's Noise: One-Offs Masking the Base Business
- GTBL standalone was capacity-constrained, not demand-constrained: Revenue was almost flat because the company was practically sold out on its old 450 cubic meter fermentation capacity, a condition that has persisted for 5–6 years.
- New facility opex hit the P&L before revenue could: The second fermentation facility started operations from 26 September, so Q2 absorbed its operating expenses while revenue benefits will only begin flowing from Q4 onwards, temporarily depressing EBITDA.
- Consolidated earnings carried three one-time burdens: An unrealised forex conversion loss of ~₹16 crores (a non-cash accounting adjustment on GTBL's JPY-denominated borrowing to TBJ, expected to reverse), only 13 days of MBJ P&L consolidated with major revenue booked before consolidation but fixed costs borne, and an exceptional expense of ₹1.2 crores for earthquake damage restoration at an MBJ plant.
- COGS spiked on a base effect, not structural cost inflation: COGS rose to ~24% of revenues this quarter versus sub-20% historically, but last quarter's COGS was unusually low (12–14%) due to inventory adjustments; this quarter appears high partly because of that base effect and some API coming through.
- Employee expenses stayed flat despite the capacity doubling: Employee benefit expenses remain around ₹4 crore per quarter with ~200 factory workers, and only a marginal increase is expected going forward because utility and other areas can manage higher capacities with the same headcount.
Patel: "We needed to transform ourselves from intermediate API fermentation company into a fermentation-based CDMO. And this is very important because it had to be fermentation-based. This is our DNA, this is our ethos."
The Capacity Story: Doubling Fermentation, Halving Energy Costs
- New fermentation capacity doubles the base: The new facility takes total capacity to 990 kiloliters, and output is expected to increase significantly this quarter, maybe to 80% of the new capacity.
- Revenue trajectory is back-end loaded: Output from the new facility starts flowing from Q3, but revenue benefits are guided to begin from Q4 FY27, at which point management expects EBITDA and EBITDA margin to come back to the original levels.
- Hybrid power plant cuts energy cost to half: The first phase (9 MW solar and one 3.15 MW wind turbine) was commissioned on 9 October; the full project with three turbines is expected by December, reducing grid dependence and improving competitiveness.
- CWIP of ₹174 crore is largely the power plant and R&D infrastructure: Once operational, the hybrid power plant will improve the P&L.
- Management declined to give peak turnover guidance for the second fermentation unit at full utilisation, telling analysts to take a "guesstimate" from the fact that capacity has doubled.
Patel: "The global fermentation capacity is 1/7 of what is required over the next 3 to 4 years. ... So I think we have to do something horribly wrong not to capture this particular opportunity with the kind of capacity that we have now and with the kind of capability we have right now."
MBJ Integration: A Technology Bet Still Being Sized
- MBJ was bought for its technology base, not its recent growth: Revenue scale was flat at ~¥750 crore from 2019 under private equity ownership, and profitability eroded in that phase, though EBITDA did improve from ~$7–8 million to ~$14–15 million over the PE holding period.
- GTBL paid a premium to Japanese norms to win the asset: Management acknowledged paying 12x EBITDA, above the 10–11x that competitive bidders offered, because of MBJ's technology base.
- The integration deep-dive is still underway: Management is conducting monthly deep-dives into two areas at a time (plasmids, large-scale fermentation, immunosuppressants, biopeptides, biologics) and expects both companies to be "very well aligned" on working together by March.
- MBJ's near-term numbers are expected flat year-on-year: Management is currently going by MBJ's own business plan without adding anything, and will only state 5-year expectations confidently by end of March.
- MBJ's hockey-stick revenue plan is back-ended to FY29–30: Management wants to pre-pone that trajectory and does not feel it is too much of a challenge, citing opportunities from the generic world and non-pharma sectors, but says it is too early to say anything definitive.
- The incentive model is being rebuilt for growth, not just margin: Under PE ownership, everyone was incentivised on EBITDA; GTBL is working on a model that combines EBITDA and growth, and is exploring giving the MDJ team exposure to Indian equity markets.
- No current MDJ products are planned to shift manufacturing to India: Future projects where MDJ does development and GTBL does manufacturing are the focus, targeting projects MDJ currently rejects because they are not viable at 35%+ EBITDA margin in Japan.
- Management declined to give an indicative payback period for the MBJ acquisition at 12x EBITDA, saying it will answer by end of March after understanding the company better.
Patel: "We can have a lot of ideas, we can have a lot of thoughts, but unless everyone is aligned, we cannot move ahead."
MDJ: The Margin Levers Already Visible
- MDJ's EBITDA margin improved from 18% to 25% through site consolidation (shutting down an old site and eliminating duplicate fixed costs) and a product mix shift on a key bioconversion product.
- That 25% margin is sustainable with room to improve: As new businesses coming in at 35%+ EBITDA margin take over in volumes, the overall EBITDA margin should increase.
- Key disclosed products are anthracyclines and josamicin: Anthracyclines involve converting synthetic processes into bioconversions across the whole doxorubicin derivative range; josamicin is the only registered source in Japan and is being relaunched globally. Other products remain under CDA or in R&D.
- The plasmid business is tiny today but central to strategy: Currently at 2–3% capacity utilisation, it is expected to increase significantly over the next 3–4 years; a pending patent could open royalty revenues from ~20 projects at various CDMOs.
- MBJ's gene therapy asset is its most advanced programme: A product for a rare neuro disease has completed Phase 2, and authorities are considering marketing approval based on that study.
- Bioconversion technology is a collaboration play: MBJ's P450 enzyme engineering technology, which converts multiple synthetic chemistry steps into a single enzymatic step, will be applied in generic spaces under profit-sharing arrangements with Indian pharmaceutical companies.
Sanofi: The Only Forward-Integration Path That Protects the Base
- The Sanofi portfolio is branded, originator, and non-competing: Management stated it is the only finished-dosage portfolio that does not cannibalise GTBL's existing intermediate customers, because it serves markets those customers do not cater to.
- API integration unlocks a gross margin leap: When the Sanofi portfolio integrates with GTBL's API capability, a process expected to take three years, gross margin moves from 55–58% to 74–75%.
- The deal is expected to close by January–February: All FDI clearances are coming through; the long-stop date is June next year, providing a fair amount of time.
- Sanofi business margin is expected at about 25% EBITDA, described as "better" than the current MDJ business.
- Funding is in place via debt and mezzanine financing: Management plans to close Sanofi with debt term sheets, consolidate all three entities for at least a quarter, then look at raising equity, stating "for sure, we have to raise equity" to make the debt position clear.
- Granular growth strategy details were withheld until after the transaction closes, when management will hold a separate meeting.
Patel: "We could not get into finished dosage forms without cannibalizing our current customers. And this is very important because this is our bread and butter. So the only portfolio that we could actually go for was a branded portfolio which was not being supplied by, or which were the markets which were not catered to by our current customers. And there is only one portfolio, that is Sanofi's portfolio."
API Forward Integration: Slow, Selective, and Margin-Protective
- GTBL now produces rifampicin, rifapentin, and rifaximin APIs internally, forward-integrated from its intermediates VIFA-S and VIFA-O.
- The 3–4 year target is to convert at least half of intermediate capacity into API: Intermediate volumes from the past should continue, with the other half converted via forward integration, growing the API business "slowly but surely."
- The approach is deliberately selective to avoid cannibalisation: Management emphasised a "right balance" between doing APIs and protecting current intermediate customers.
- The Sanofi portfolio provides a security layer for the base business: Beyond adding good EBITDA, forward integration into Sanofi's branded portfolio is framed as protecting and improving margins on every kilo of intermediate manufactured.
Patel: "We want to do APIs, we are going to do APIs but selectively, not in a way whereby we are cannibalizing our current customers. So I think there's got to be a right balance in terms of what we are doing right now and where we want to go with the APIs."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| New fermentation revenue | Revenue benefits from new 990 KL capacity to begin flowing | Q3 FY27 onwards |
| EBITDA margin recovery | GTBL EBITDA and EBITDA margin to return to original levels as new capacity revenue flows in | Q3 FY27 onwards |
| Forex loss reversal | Unrealised ~₹16 crore forex loss expected to reverse with favourable JPY movement | Next quarter(s) |
| Hybrid power plant completion | Full project (3 wind turbines) up and running | By December |
| MDJ-GTBL strategic alignment | Both companies "very well aligned" on working together; incentive model combining EBITDA and growth finalised | By March (end of FY27) |
| MDJ 5-year expectations | Management to state what it exactly expects out of MDJ over the next 5 years | By end of March |
| Sanofi transaction close | Deal closure subject to FDI clearances | January–February (long-stop June) |
| Sanofi growth strategy disclosure | Granular details to be shared in a separate meeting | After transaction closes |
| NCD India partial repayment | Partial repayment through preferential issue proceeds, awaiting stock exchange approval | Undated |
| API forward integration | At least half of intermediate capacity converted into API | Over next 3–4 years |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue (standalone) | Almost flat, sold out on old fermentation capacity |
| EBITDA | Temporarily impacted, operating expenses of new fermentation facility hit P&L; revenue benefits expected from Q4 FY27 |
| EBITDA margin | Expected to come back to original levels once new facility revenue flows in from Q4 FY27 |
| PAT | Down, due to temporary acquisition-related financing costs |
| Consolidated unrealized forex loss | ~₹16 cr, non-cash accounting adjustment expected to reverse with favorable currency fluctuations |
| MBJ consolidation period | 13 days only (ownership transferred 18th September); major September revenue booked in first 17 days, resulting in MBJ P&L loss for the period |
| Exceptional expenses | ₹1.2 cr, earthquake in Japan in July end impacted one MBJ plant |
| GTBL fermentation capacity | 990 kiloliters total, doubled from 450 KL; new facility started operating from September 26 |
| Hybrid power plant | 18.45 MW (9 MW solar, 9.9 MW wind); Phase 1 commissioned 9th October; full project by December; energy cost expected to reduce to half |
| MBJ turnover (annual) | Close to about ₹550 cr |
| MBJ EBITDA margin (FY26) | 25%, improved from 20% in FY24 |
| MBJ acquisition purchase consideration | ₹1,351 cr, covering 100% equity buyout, stock option rights, and employee bonuses |
| MBJ existing loans refinanced | ~₹632 cr, funded via Singapore NCD of ₹43 cr and ₹189 cr from MBJ's own books |
| MBJ capacity utilization | Each block at about 20–30%, some even lower |
| MBJ new project EBITDA margin | Over 35% |
| Sanofi portfolio revenue (annual) | About €62 million |
| Sanofi portfolio gross margin | 55–58% currently; expected to reach 74–75% after API integration in 3 years |
| Sanofi portfolio historical growth | 5–6% CAGR over last 5 years |
| Mezzanine financing cost | 16–17% currently; expected to come down to about 9% after refinancing, with Japan rate possibly 4% or less |
| GTBL free cash flow expectation | Around ₹15–20 cr |
| MBJ free cash flow expectation | Easily around ₹90–100 cr (combined entity, excluding acquisitions and incremental capex) |